Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy
Public ClinicalTrials.gov record NCT06215859. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multi-Center, Randomized, Double-Blind, Placebo (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.
Study identification
- NCT ID
- NCT06215859
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 579 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 28, 2023
- Primary completion
- Jan 30, 2025
- Completion
- Mar 11, 2025
- Last update posted
- Feb 9, 2026
2023 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator site 210 | Sheffield | Alabama | 35660 | — |
| Investigator site 213 | Phoenix | Arizona | 85053 | — |
| Investigator site 202 | Anaheim | California | 92801 | — |
| Investigator site 222 | Bakersfield | California | 93301 | — |
| Investigator site 208 | Riverside | California | 92501 | — |
| Investigator site 211 | Miami | Florida | 33014 | — |
| Investigator site 206 | Tampa | Florida | 33613 | — |
| Investigator site 207 | Atlanta | Georgia | 30331 | — |
| Investigator site 205 | Wichita | Kansas | 67214 | — |
| Investigator site 212 | Bellaire | Texas | 77401 | — |
| Investigator site 215 | Carrollton | Texas | 75006 | — |
| Investigator site 204 | Houston | Texas | 77008 | — |
| Investigator site 216 | McAllen | Texas | 78501 | — |
| Investigator site 219 | San Antonio | Texas | 78229 | — |
| Investigator site 203 | San Antonio | Texas | 78240 | — |
| Investigator site 214 | San Antonio | Texas | 78258 | — |
| Investigator site 201 | Salt Lake City | Utah | 84107 | — |
| Investigator site 224 | Eau Claire | Wisconsin | 54701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06215859, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2026 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06215859 live on ClinicalTrials.gov.